about
Sequencing of chemotherapy and radiotherapy for early breast cancerTaxanes for adjuvant treatment of early breast cancerSequencing of chemotherapy and radiation therapy for early breast cancerProgress in adjuvant chemotherapy for breast cancer: an overviewMaternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literatureAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineSystemic treatment strategies for triple-negative breast cancer.High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.Docetaxel/anthracycline combinations for breast cancer treatmentAdjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patientsThe synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinomaTaxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Pregnancy-associated breast cancer: optimal treatment options.A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancerAn exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.Breast cancer (non-metastatic)Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias.CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsIncidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patientsCost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.Presentation and management of docetaxel-related adverse effects in patients with breast cancerProphylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapyTriple-negative breast cancer: role of specific chemotherapy agentsBreast cancer before age 40 years.Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesNew Therapeutic Options for Breast Cancer during Pregnancy.Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing folliclesChemotherapy-induced cardiotoxicity.Medical treatment of early breast cancer. III: chemotherapy.
P2860
Q24197599-06A14F62-2A56-4509-8E97-8D20589347D1Q24242987-07775FB6-98A4-4693-A86A-35BA1DA78467Q24243984-417AC815-0FEF-49B5-A1DD-550F361BD9C0Q26798078-49E5C8B3-4B84-473C-82EF-A057EF9E3F97Q26827698-6B6804C0-AE5B-43A7-81CA-368A752266A3Q26853619-5B9454A6-C534-453B-A476-36CC3F92A5E3Q27691414-24CF0911-2186-44FB-B94C-C4411FC1AB93Q27851775-6C14CC75-7714-46BB-B9A7-A87831EFE370Q28288899-8B5E19B4-54F6-47F8-86F0-CEDA8EAFB393Q28477739-AF43E19D-E49E-47B2-A4BF-6851F1CDF76BQ28538702-76FC4387-8DB0-4198-B0AC-0D5B69FCAF83Q30251429-01A65A78-17A9-47B9-9338-7FFAAF532603Q30426275-251A13FE-1E57-47FF-B538-40C872C52861Q30435881-52A4CF2E-5A70-4E95-BA6B-893482CE862FQ30439393-02E12D2C-00FB-41F6-A9A9-C5995C5A0DA3Q33281956-7A5E2E07-E492-48E9-BDF3-0B12EC8417C9Q33305210-3B4CC3B2-9468-4908-9DA6-EA971D689C22Q33370705-80548C39-63A2-4AAC-B1D8-B4166FF7AA52Q33383830-5EEB93DD-0392-4C15-B58F-8E63E9C71F82Q33418714-8EAFDDC3-3FB2-4712-BBE2-8FF70C271B29Q33441582-B49DC0AE-B266-4B51-AF60-A9F335A7C294Q33446778-FF41D155-D8D9-4415-A1DF-5DEFEA9F27E5Q33522784-3DCB4798-1747-4C73-8D38-6FF8A5F4D2B9Q33591741-3D7BF85A-21C8-4AFD-B954-3A300107BFC9Q33601886-2563D989-DEF5-4804-85A1-001B3A541107Q33633585-F6041D5E-0385-460A-82D2-F557F1580F72Q33680393-DE2C8C28-F546-498D-B3D6-D6FC063D035BQ33698286-1499B310-E59C-4165-BE1F-142ED4EB3A70Q33756369-B49D1CBD-4866-47D0-938D-E2580FC01CCBQ33785011-3CB4DE2C-1DB4-4BCA-8550-A9E3CF17F133Q33800180-E306A62E-89BF-4BE0-A747-6B1509C08A2CQ33900930-2C57E31F-14B0-48A8-AE17-E5CC1326939BQ33948726-C53DC48A-C067-4F31-922C-B5E03343F814Q34023749-3AC632ED-5AFD-4511-9B5C-86E24B75255CQ34096331-45B7DCCB-DC7D-4A32-97D6-D2384B14F261Q34184798-B7587298-FDA9-40F4-83C6-99F8A451F306Q34199348-1C796895-2BA5-4888-BAD6-D8F8EA13CADDQ34230276-6F4F09FF-0E70-4771-9E9D-0B531BFD6D8FQ34258080-3402DCF0-92FA-442C-A4C4-1D5896FE142CQ34276260-2579AA30-570E-47F1-9973-45193EDB0685
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Adjuvant docetaxel for node-positive breast cancer.
@en
Adjuvant docetaxel for node-positive breast cancer.
@nl
type
label
Adjuvant docetaxel for node-positive breast cancer.
@en
Adjuvant docetaxel for node-positive breast cancer.
@nl
prefLabel
Adjuvant docetaxel for node-positive breast cancer.
@en
Adjuvant docetaxel for node-positive breast cancer.
@nl
P2093
P356
P1476
Adjuvant docetaxel for node-positive breast cancer.
@en
P2093
Alessandro Riva
Alvaro Rodriguez-Lescure
Breast Cancer International Research Group 001 Investigators
Bruce Colwell
Camille Loret
Catherine Prady
Charles Vogel
Charles Weaver
David Walde
P304
P356
10.1056/NEJMOA043681
P407
P577
2005-06-01T00:00:00Z